Live Breaking News & Updates on Ipavibart

AstraZeneca:Phase III Trial Of Sipavibart Met Main Goal In Preventing COVID-19 In Immunocompromised Patients

LONDON (dpa-AFX) - AstraZeneca's (AZN.L, AZN) sipavibart demonstrated a statistically significant reduction in the incidence of symptomatic COVID-19 compared to control (tixagevimab/cilgavimab

London , City-of , United-kingdom , More-such-health-news , Ihr-portfolio , Astrazeneca , Hase , Rial , Ipavibart , Ain , Oal